Evidence map›Paper›PMID 37111681›Full record

ArticlePharmaceutics2023

Versatile Solid Modifications of Multicomponent Pharmaceutical Salts: Novel Metformin-Rhein Salts Based on Advantage Complementary Strategy Design.

Mingchao Yu, Meidai Liang, Qi An, Wenwen Wang, Baoxi Zhang, Shiying Yang, Jian Zhou, Xiuying Yang, Dezhi Yang, Li Zhang and 2 more

Open access · goldAbstract read
In one paragraph

Article in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
2.0field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Mingchao YuInstitute of Materia Medica, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100050, China.ORCID 0000-0001-5676-8551
Meidai LiangInstitute of Materia Medica, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100050, China.
Qi AnInstitute of Materia Medica, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100050, China.
Wenwen WangInstitute of Materia Medica, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100050, China.
Baoxi ZhangInstitute of Materia Medica, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100050, China.
Shiying YangInstitute of Materia Medica, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100050, China.ORCID 0000-0001-5525-169X
Jian ZhouInstitute of Materia Medica, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100050, China.
Xiuying YangInstitute of Materia Medica, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100050, China.
Dezhi YangInstitute of Materia Medica, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100050, China.ORCID 0000-0002-3159-4126
Li ZhangInstitute of Materia Medica, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100050, China.
Guanhua DuInstitute of Materia Medica, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100050, China.
Yang LuInstitute of Materia Medica, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100050, China.
Chinese Academy of Medical Sciences & Peking Union Medical College · CN

Funding

CAMS Innovation Fund for Medical Sciences 2022-I2M-1-015CAMS Innovation Fund for Medical Sciences 2022-I2M-JB-010Key R&D Program of Shan Dong Province 2021ZDSYS26National Science Foundation of China 22278443
6 · The paper itself

Abstract

This study aimed to develop an effective treatment for diabetes and diabetic complications, based on the advantage complementary strategy of drug-drug salt, by designing and synthesizing the multicomponent molecular salts containing metformin (MET) and rhein (RHE). Finally, the salts of MET-RHE (1:1), MET-RHE-H

Indexed as

diabetic complicationsdrug–drug salthygroscopicityhypoglycemic activitypolymorphismsolubility

Identifiers

PMID37111681
PMCPMC10142746
OpenAlexW4363679587

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.